These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16461999)

  • 1. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva.
    Nakamura T; Ohbayashi M; Toda M; Hall DA; Horgan CM; Ono SJ
    Immunol Res; 2005; 33(3):213-21. PubMed ID: 16461999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The murine CCR3 receptor regulates both eosinophilia and hyperresponsiveness in IgE-mediated allergic conjunctivitis.
    Fukuda K; Kuo CH; Morohoshi K; Liu FT; Ono SJ
    Br J Ophthalmol; 2012 Aug; 96(8):1132-6. PubMed ID: 22694967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, selective, and orally available antagonist for CC chemokine receptor 3.
    Morokata T; Suzuki K; Masunaga Y; Taguchi K; Morihira K; Sato I; Fujii M; Takizawa S; Torii Y; Yamamoto N; Kaneko M; Yamada T; Takahashi K; Shimizu Y
    J Pharmacol Exp Ther; 2006 Apr; 317(1):244-50. PubMed ID: 16339911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional analyses before and after suppression of immediate hypersensitivity reactions by CCR3 blockade in eyes with experimental allergic conjunctivitis.
    Komatsu N; Miyazaki D; Tominaga T; Kuo CH; Namba S; Takeda S; Higashi H; Inoue Y
    Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5307-13. PubMed ID: 18658092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of chemokines in ocular allergy and possible therapeutic strategies.
    Miyazaki D; Nakamura T; Komatsu N; Nawata N; Ikeda Y; Inoue Y; Higashi H; Ono SJ
    Cornea; 2004 Nov; 23(8 Suppl):S48-54. PubMed ID: 15448480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.
    Suzuki K; Morokata T; Morihira K; Sato I; Takizawa S; Kaneko M; Takahashi K; Shimizu Y
    Eur J Pharmacol; 2007 Jun; 563(1-3):224-32. PubMed ID: 17336292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation.
    Das AM; Vaddi KG; Solomon KA; Krauthauser C; Jiang X; McIntyre KW; Yang XX; Wadman E; Welch P; Covington M; Graden D; Yeleswaram K; Trzaskos JM; Newton RC; Mandlekar S; Ko SS; Carter PH; Davies P
    J Pharmacol Exp Ther; 2006 Jul; 318(1):411-7. PubMed ID: 16614169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists.
    Bryan SA; Jose PJ; Topping JR; Wilhelm R; Soderberg C; Kertesz D; Barnes PJ; Williams TJ; Hansel TT; Sabroe I
    Am J Respir Crit Care Med; 2002 Jun; 165(12):1602-9. PubMed ID: 12070060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.
    Suzuki K; Morokata T; Morihira K; Sato I; Takizawa S; Kaneko M; Takahashi K; Shimizu Y
    Biochem Biophys Res Commun; 2006 Jan; 339(4):1217-23. PubMed ID: 16343433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences.
    Miyazaki D; Liu G; Clark L; Ono SJ
    Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3850-5. PubMed ID: 11053285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
    De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
    J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin.
    Teixeira MM; Wells TN; Lukacs NW; Proudfoot AE; Kunkel SL; Williams TJ; Hellewell PG
    J Clin Invest; 1997 Oct; 100(7):1657-66. PubMed ID: 9312163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus.
    Stebbins KJ; Broadhead AR; Musiyenko A; Barik S; Scott JM; Truong YP; Stearns BA; Hutchinson JH; Prasit P; Evans JF; Lorrain DS
    Int Arch Allergy Immunol; 2012; 157(3):259-68. PubMed ID: 22042170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis.
    Fukuda K; Ohbayashi M; Morohoshi K; Zhang L; Liu FT; Ono SJ
    J Allergy Clin Immunol; 2009 Oct; 124(4):827-33.e2. PubMed ID: 19660804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.
    Ma W; Bryce PJ; Humbles AA; Laouini D; Yalcindag A; Alenius H; Friend DS; Oettgen HC; Gerard C; Geha RS
    J Clin Invest; 2002 Mar; 109(5):621-8. PubMed ID: 11877470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo.
    Sabroe I; Conroy DM; Gerard NP; Li Y; Collins PD; Post TW; Jose PJ; Williams TJ; Gerard CJ; Ponath PD
    J Immunol; 1998 Dec; 161(11):6139-47. PubMed ID: 9834099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in CCR3 antagonists.
    De Lucca GV
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):516-24. PubMed ID: 16889234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases.
    Elsner J; Escher SE; Forssmann U
    Allergy; 2004 Dec; 59(12):1243-58. PubMed ID: 15507091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade.
    Miyazaki D; Nakamura T; Ohbayashi M; Kuo CH; Komatsu N; Yakura K; Tominaga T; Inoue Y; Higashi H; Murata M; Takeda S; Fukushima A; Liu FT; Rothenberg ME; Ono SJ
    Int Immunol; 2009 Feb; 21(2):187-201. PubMed ID: 19147836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.